---
title: tirzepatide
popular_name: "Tirzepatide"
developmental_codes: ["Tirzepatide", "GIP/GLP-1 dual agonist"]
street_names: ["Tirzepatide", "Mounjaro", "Zepbound"]
product_names: ["Mounjaro", "Zepbound"]
description: "Tirzepatide is an antidiabetic medication used to treat typeÂ 2 diabetes and for weight loss. Tirzepatide is administered via subcutaneous injections. In the United States, it is sold under the brand name Mounjaro for diabetes treatment and Zepbound for weight loss and treatment of obstructive sleep apnea."
short_description: "Dual GIP/GLP-1 agonist for type 2 diabetes and superior weight loss (up to 20%+), sold as Mounjaro and Zepbound."
benefits: ["Superior weight loss (up to 20%+ body weight)", "Excellent appetite control", "Improved insulin sensitivity", "Better blood sugar management", "Reduced cardiovascular risk factors", "Enhanced metabolic rate", "Improved lipid profiles", "Aids in fat loss and metabolism", "Improves sleep quality"]
dosage_levels: ["Starting dose: 2.5mg weekly (subcutaneous)", "Titration: 5mg weekly after 4 weeks", "Therapeutic: 10mg weekly", "Maximum: 15mg weekly for maximum weight loss"]
research: ["wikipedia: https://en.wikipedia.org/wiki/tirzepatide", "pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=tirzepatide", "clinical trials: https://clinicaltrials.gov/search?term=tirzepatide", "pubmed study: https://pubmed.ncbi.nlm.nih.gov/41100405/", "pubmed study: https://pubmed.ncbi.nlm.nih.gov/41098876/"]
tags: ["fat loss", "subcutaneous"]
affiliate_links: []
is_natty: false
created_at: 2025-10-17T08:26:21.286Z
last_updated_at: 2025-10-19T03:36:07.759Z
---